05:52 PM EDT, 06/04/2024 (MT Newswires) -- Cellectis ( CLLS ) said late Tuesday that the European Commission has granted an orphan drug designation to the company's product candidate UCART22 to treat acute lymphoblastic leukemia.

The European Medicines Agency considered the significant benefit of UCART22 has been demonstrated based on the preliminary data generated with UCART22 in heavily pretreated patients who were relapsed or refractory to approved medicinal products.